Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Fluticasone furoate
Drug ID BADD_D00946
Description Fluticasone furoate is a synthetic glucocorticoid available as an inhaler and nasal spray for various inflammatory indications[FDA Label][F4364]. Fluticasone furoate was first approved in 2007[L5965].
Indications and Usage Fluticasone furoate is indicated as an inhaler for the treatment and management of asthma by prophylaxis[FDA Label][F4364]. The fluticasone furoate nasal spray is indicated for treating season and perennial allergic rhinitis[FDA Label][A177130].
Marketing Status approved
ATC Code R01AD12; R03BA09
DrugBank ID DB08906
KEGG ID D06315
MeSH ID C523187
PubChem ID 9854489
TTD Drug ID D0Y7JU
NDC Product Code 47848-057; 64918-1915; 0135-0615; 64918-1910; 64918-1916; 22552-0042; 63379-083; 55018-302; 58175-0553; 0135-0616; 63592-3370; 0173-0874; 0173-0888; 50090-5967; 49076-6452; 59057-010; 0173-0876; 50090-6075; 15308-2021; 52482-008; 63379-084; 49076-6451; 59057-009; 64918-1117
UNII JS86977WNV
Synonyms fluticasone furoate
Chemical Information
Molecular Formula C27H29F3O6S
CAS Registry Number 397864-44-7
SMILES CC1CC2C3CC(C4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)SCF)OC(=O)C5=CC=CO5)C)O)F)C)F
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Neoplasm malignant16.16.01.001--Not Available
Nerve compression17.09.02.002; 12.01.12.001--Not Available
Nervous system disorder17.02.10.001--Not Available
Nonspecific reaction08.01.03.040--Not Available
Obsessive-compulsive disorder19.06.05.002--Not Available
Oral discomfort07.05.05.001--Not Available
Palpitations02.11.04.012--
Panic attack19.06.04.001--Not Available
Parosmia22.04.03.007; 17.04.04.002--Not Available
Pharyngitis11.01.13.003; 07.05.07.004; 22.07.03.004--
Pleural effusion22.05.02.002--
Pneumothorax22.05.02.003--
Productive cough22.02.03.005--
Pulmonary congestion24.03.08.001; 22.01.03.002; 02.05.02.002--Not Available
Pulmonary fibrosis22.01.02.006--
Pulmonary oedema22.01.03.003; 02.05.02.003--
Pulmonary thrombosis24.01.06.002; 22.06.02.003--Not Available
Pyrexia08.05.02.0030.000611%
Rash23.03.13.0010.001956%Not Available
Renal disorder20.01.02.002--Not Available
Respiration abnormal22.02.01.041--Not Available
Respiratory disorder22.02.07.002--Not Available
Respiratory failure22.02.06.002; 14.01.04.003--
Rhinorrhoea22.12.03.021--
Sinus congestion22.04.06.001--Not Available
Skin disorder23.03.03.007--Not Available
Sleep apnoea syndrome22.02.01.013; 19.02.05.002; 17.15.05.001--
Somnolence19.02.05.003; 17.02.04.0060.000611%
Sputum discoloured22.02.03.010--Not Available
Systemic lupus erythematosus23.03.02.006; 15.06.02.003; 10.04.03.004--Not Available
The 4th Page    First    Pre   4 5 6    Next   Last    Total 6 Pages